Latest Pathology News

Amplia Therapeutics has announced a second confirmed complete response in its ACCENT trial for advanced pancreatic cancer, a notably rare achievement in this challenging disease.

Amplia Therapeutics has reported a rare pathological complete response in a patient from its ACCENT trial, highlighting promising potential for its drug narmafotinib in treating advanced pancreatic cancer.

INOVIQ Limited has revealed promising data for its EXO-OC™ ovarian cancer screening test, demonstrating exceptional accuracy and flawless detection of early-stage cancers. This innovation could transform early diagnosis and treatment outcomes for women worldwide.

Optiscan Imaging Ltd has reached a pivotal milestone with the completion of its cloud-based telepathology software MVP, enabling secure, real-time remote collaboration for digital pathology.

Alterity Therapeutics is set to present compelling Phase 2 clinical trial results for ATH434 at the 2025 International Multiple System Atrophy Congress, highlighting slowed disease progression and biomarker engagement in MSA patients.

Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.

Alterity Therapeutics has secured FDA Fast Track designation for ATH434, its lead candidate for treating Multiple System Atrophy, potentially speeding up regulatory review and bringing hope to patients with this rare neurodegenerative disorder.

Healius Limited has completed the $822 million cash sale of Lumus Imaging to Affinity Equity Partners, setting the stage for a strategic refocus on pathology and a substantial special dividend payout.

Patrys Limited advances its PAT-DX3 therapy development for inflammatory diseases while navigating cash flow challenges and pursuing partnerships to sustain operations.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

Charter Hall Social Infrastructure REIT delivered a solid 2025 half-year performance, maintaining distribution guidance while enhancing its portfolio through key acquisitions and divestments. The REIT’s outlook brightens with an increased full-year distribution forecast.

Charter Hall Social Infrastructure REIT reported solid half-year results for 1H FY25, underpinned by strong earnings, active portfolio management, and an upgraded distribution guidance. The REIT’s acquisition of a high-yield pathology laboratory and divestment of childcare assets highlight its strategic repositioning.